Director Amir Inamdar submitted a Form 3 Initial Statement of Beneficial Ownership with the SEC on October 26, 2026, disclosing his holdings in Helus Pharma Inc. (NASDAQ:HELP) as of the event date of October 13, 2026.

Key Highlights

  • Reporting person: Amir Inamdar, identified as a Director of Helus Pharma Inc.
  • Indirect common share holding: 224,332 common shares held indirectly through Zephyr Life Sciences Ltd., a United Kingdom corporation owned and controlled by Inamdar.
  • Direct common share holding: 3,490 common shares held directly by the reporting person.
  • Unvested RSUs: 66,668 restricted share units (RSUs) held indirectly through Zephyr Life Sciences Inc., each representing the right to receive one common share.
  • RSU grant date: The 100,000 RSUs were granted on October 1, 2025, with a quarterly vesting schedule over three years.
  • Filing date: Signed and filed October 26, 2026, covering the event date of October 13, 2026.

Inamdar's Initial Ownership Position in Helus Pharma

According to the filing, Amir Inamdar reported beneficial ownership of Helus Pharma Inc. common shares through two lines of holding. A total of 224,332 common shares are held indirectly through Zephyr Life Sciences Ltd., described in the filing as "a United Kingdom corporation owned and controlled by the reporting person." An additional 3,490 common shares are held directly by Inamdar in his own name.

The filing also discloses derivative securities in the form of RSUs. On October 1, 2025, the reporting person was granted 100,000 RSUs, vesting in installments: 8,333 RSUs vested on January 6, 2026, with the remainder vesting quarterly on November 20, February 20, May 20, and August 20 over three years until fully vested. As of the filing date, 66,668 RSUs remain unvested from that October 2025 grant. These RSUs are held indirectly through Zephyr Life Sciences Inc., and each unit represents a right to receive one Helus Pharma common share, according to the filing.

Helus Pharma Inc., which trades on NASDAQ under the symbol HELP, is a pharmaceutical company incorporated under its issuer name as stated on the form cover. The Form 3 is a one-time initial disclosure required under Section 16(a) of the Securities Exchange Act of 1934 when an individual becomes a reporting person, such as upon becoming a director. Inamdar's address is listed as care of Helus Pharma Inc., 100 King Street West, Suite 5600, Toronto, Ontario, Canada.

What Was Disclosed

Amir Inamdar, a Director at Helus Pharma Inc. (NASDAQ:HELP), filed a Form 3 on October 26, 2026, reporting beneficial ownership of 224,332 indirect and 3,490 direct common shares, along with 66,668 unvested RSUs held indirectly through Zephyr Life Sciences Inc.